After observing the tumor size, weight, and survival for 60 days, they found that the nanoliposomal anti‐PCSK9 vaccine could alleviate tumor growth by 21.2%, and prolong survival by 4.2%, even though the difference was not significant. The gene discussed is PCSK9; the disease is neoplasm.